These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38289775)

  • 1. Primary Systemic Amyloidosis: A Case Report.
    Oli SS; Jha A; Karki A; Sapkota S; Adhikari L
    JNMA J Nepal Med Assoc; 2023 Oct; 61(266):822-824. PubMed ID: 38289775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review.
    Kumar S; Grell GR; Joseph G; Wang JC
    J Investig Med High Impact Case Rep; 2022; 10():23247096221133191. PubMed ID: 36300416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
    Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
    Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroduodenal Involvement in AL Amyloidosis: Case Report and Literature Review.
    Ramachandran R; Grantham T; Isaac-Coss G; Etienne D; Reddy M
    J Investig Med High Impact Case Rep; 2024; 12():23247096241237759. PubMed ID: 38462925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AL-Kappa Primary Amyloidosis with Apolipoprotein A-IV Deposition.
    Ishimitsu A; Tojo A; Hirao J; Yokoyama S; Ohira T; Murayama Y; Ishimitsu T; Kang D; Honda K; Ehara T; Ishida K; Ueda Y
    Intern Med; 2022; 61(6):871-876. PubMed ID: 35296622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic veno-occlusive disease may be a rare characteristic of hepatic involvement in systemic amyloidosis: case report and literature review.
    Zhu TY; Zhou GH; Chen XH; Teng XD; Sun JH
    J Int Med Res; 2020 Feb; 48(2):300060520904857. PubMed ID: 32090649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiorgan involvement by amyloid light chain amyloidosis.
    Li G; Han D; Wei S; Wang H; Chen L
    J Int Med Res; 2019 Apr; 47(4):1778-1786. PubMed ID: 30803274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent Acute Heart Failure and Renal Failure in Amyloid Light Chain Amyloidosis.
    Cass K; Luna L; Kivlin W; Fechter B; Paudel H
    WMJ; 2024 Jul; 123(3):225-228. PubMed ID: 39024153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal failure due to primary amyloidosis: a case report and literature review.
    de Mello RA; Marques Santos DS; Freitas-Silva MP; Andrade JA
    Sao Paulo Med J; 2011 May; 129(3):176-80. PubMed ID: 21755253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin Light Chain Amyloidosis Presenting as Inferior Vena Cava Thrombosis.
    Axentiev A; Rozik M; Slama E; Setya V
    Am Surg; 2023 Jun; 89(6):2788-2790. PubMed ID: 34743583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
    Lewis E; McCulloch S; Mahe E; Bahlis N; Neri P; Tay J; Duggan P; Jimenez-Zepeda VH
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e331-e334. PubMed ID: 37532664
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
    Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
    Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary systemic amyloidosis with skin and cardiac involvement: a case report.
    Trajber Horvat A; Trčko K; Jurčić V; Marko PB
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Mar; 27(1):45-47. PubMed ID: 29589647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive chorioretinal involvement in a patient with light-chain (AL) amyloidosis: a case report.
    Augstburger E; Sahel JA; Audo I
    BMC Ophthalmol; 2020 Feb; 20(1):59. PubMed ID: 32085748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
    Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
    Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
    [No Abstract]   [Full Text] [Related]  

  • 20. A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis.
    Palladini G; Celant S; Milani P; Summa V; Affronti G; Olimpieri PP; Petraglia S; Foli A; Nuvolone M; Merlini G; Russo P;
    Leuk Lymphoma; 2022 Jan; 63(1):205-211. PubMed ID: 34448427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.